Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-25 of 89 for your search:
Cancer Type:
aggressive, contiguous stage II adult non-Hodgkin lymphoma
Stage/Subtype of Cancer:
aggressive, contiguous stage II adult non-Hodgkin lymphoma
Country:
U.S.A.
Trial Type:
Treatment
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's Lymphoma
Phase:
Phase IV
Type:
Natural history/Epidemiology, Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
U2963n
, NCT00097565
2.
Phase II/III Study of Disease-Specific High-Dose Conditioning Regimens Followed by Autologous Stem Cell Transplantation (Single or Tandem) in Patients With Hematologic Malignancies or Solid Tumors
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
4 and over
Sponsor:
NCI
Protocol IDs:
RPCI-I-72806
, I 72806, NCT00536601
3.
Non-Myeloablative Allogeneic HSCT From HLA Matched Related Donors for the Treatment of Low Grade B Cell Malignancies
Phase:
Phase III, Phase II
Type:
Treatment
Status:
Active
Age:
19 to 70
Sponsor:
Other
Protocol IDs:
F080429003
, UAB-0775, NCT00714259
4.
Phase III Randomized Study of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) Versus Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin and Rituximab (EPOCH-R) in Patients With Previously Untreated De Novo Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
CALGB-50303
, ECOG-50303, NCI-05-C-0252, NCT00118209
5.
Effect of Tight Control of Blood Glucose During Hyper-CVAD Chemotherapy For Acute Lymphocytic Leukemia (ALL)
Phase:
Phase III
Type:
Supportive care, Treatment
Status:
Active
Age:
15 and over
Sponsor:
Other
Protocol IDs:
2004-0107
, NCT00500240
6.
A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma (RATE)
Phase:
Phase III
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
U4391g
, NCT00719472
7.
Phase I/II Study of Epstein Barr Virus Specific Cytotoxic T Lymphocytes from a Normal HLA-Compatible Donor in the Treatment of Patients With Epstein Barr Virus Associated Lymphomas and Other Lymphoproliferative Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Not specified
Sponsor:
Other
Protocol IDs:
MSKCC-95024
, NCI-V95-0685, NCT00002663
8.
Phase I/II Study of Fenretinide and Rituximab in Patients With B-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
WU-6071
, 6071, FHCRC-6071, NCI-6957, 6957, UWCC-UW-6071, UWCC-06-0644-H/A, NCT00288067
9.
A Study of SB-743921 in Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
CY 2121
, NCT00343564
10.
Phase I/II Study of Reduced-Intensity Preparative Regimen Comprising Fludarabine, Busulfan, and Alemtuzumab Followed By Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematological Malignancies or Other Diseases
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
70 and under
Sponsor:
Other
Protocol IDs:
BCM-H-19386
, BCM-FAB, H 19386, NCT00625144
11.
Phase I/II Study of Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Patients With Relapsed or Primary Refractory Lymphoid Malignancies or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
PSOC-2302
, 6632, FHCRC-IR-6632, NCT00601718
12.
Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
SCRI LYM 58
, NCT00633594
13.
A Phase I/II Trial of VR-CHOP in Lymphoma Patients
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
IRB# 29960007
, NCT00634179
14.
Unrelated Cord Blood Transplant Plus a Haplo-Identical (Half-Matched), T-Cell Depleted Stem Transplant From a Related Donor for Subjects With High Risk Malignancies
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
0 to 55
Sponsor:
Other
Protocol IDs:
8717
, NCT00673114
15.
Study of the Safety and Tolerability of PCI-24781 in Patients With Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Pharmaceutical / Industry
Protocol IDs:
PCYC-0403
, NCT00724984
16.
Phase I/II Study of Vorinostat, Cladribine, and Rituximab in Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 to 85
Sponsor:
NCI, Pharmaceutical / Industry
Protocol IDs:
OHSU-4180
, 4180, OHSU-HEM-08002-L, MERCK-OHSU-4180, NCT00764517
17.
Phase I/II Study of Rituximab, Cladribine, and Temsirolimus in Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCCTG-N078D
, N078D, NCT00787969
18.
SAHA + CHOP in Untreated T-Cell Non-Hodgkin's Lymphoma
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
2008-0484
, NCT00787527
19.
Phase I/II Study of T-Cell-Reduced Unrelated Donor Peripheral Blood Stem Cell Transplantation After Reduced-Intensity Conditioning Comprising Pentostatin and Low-Dose Total-Body Irradiation in Patients With Hematological Malignancies
Phase:
Phase II, Phase I
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
19 to 75
Sponsor:
NCI
Protocol IDs:
UNMC-16407
, 164-07, NCT00816413
20.
Phase II Study of Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Disease or Cancer
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
8 to 80
Sponsor:
NHLBI
Protocol IDs:
NHLBI-99-H-0050
, NCT00003838
21.
Phase II Study of Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematologic Malignancy
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
65 and under
Sponsor:
NCI
Protocol IDs:
CPMC-IRB-AAAA5571
, CPMC-CAMP-016, NCI-G00-1891, NCT00008216
22.
Phase II Study of Rituximab and High-Intensity Chemotherapy With Filgrastim (G-CSF) Support in Patients With Previously Untreated Burkitt's Lymphoma or Burkitt's Leukemia
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
16 and over
Sponsor:
NCI
Protocol IDs:
CALGB-10002
, NCT00039130
23.
Phase II Study of Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (EPOCH) With Rituximab and Filgrastim (G-CSF) in Patients With Stage I-IV Non-Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over for Burkitt's lymphoma
Sponsor:
NCI
Protocol IDs:
NCI-93-C-0133
, CRB-9307, NCI-MB-303, NCI-T93-0023N, T93-0023, NCT00018980
24.
Phase II Pilot Study of Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody (MDX-CTLA4) in Patients With Follicular or Mantle Cell Lymphoma, Colon Cancer, Prostate Cancer Refractory to Vaccine Therapy (Prostate cancer and mantle cell lymphoma closed to accrual as of 3/10/2005; colon cancer closed to accrual as of 9/28/05),Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI
Protocol IDs:
NCI-02-C-0284
, NCI-5744, NCT00047164, 5744
25.
Phase II Study of Rituximab, Cyclophosphamide, Pegylated Doxorubicin HCl Liposome, Vincristine, and Prednisone in Older Patients With Previously Untreated Aggressive Diffuse Large B-Cell Stage II-IV Lymphoma
Phase:
Phase II
Type:
Treatment
Status:
Active
Age:
61 and over
Sponsor:
NCI
Protocol IDs:
MDA-CCOP-2004-0305
, 2004-0305, 6485, NCI-6485, NCT00101010
Select All on Page
1
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute